Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

S.L. Hauser, A. Bar-Or, G. Comi, G. Giovannoni, H.-P. Hartung, B. Hemmer, F. Lublin, X. Montalban, K.W. Rammohan, K. Selmaj, A. Traboulsee, J.S. Wolinsky, D.L. Arnold, G. Klingelschmitt, D. Masterman, P. Fontoura, S. Belachew, P. Chin, N. Mairon, H. GarrenL. Kappos, Paola Crociani

Research output: Contribution to journalArticle

Cite this

Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., Traboulsee, A., Wolinsky, J. S., Arnold, D. L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., ... Crociani, P. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221-234. https://doi.org/10.1056/NEJMoa1601277